Ultra-sensitive diagnostics platform combining photodynamic therapy reagents with a digital readout

“我们现在生活在这样一个时代，对许多患者来说，个性化精准医疗是一种现实，可以带来更好的健康结果。这种个性化需要获得适当的诊断工具，以便在正确的时间选择正确的患者进行正确的治疗。虽然使用现有的诊断工具可以检测到大量的疾病标记物，以供患者选择，但由于检测的灵敏度有限，仍有相当数量的疾病领域无法在临床环境中进行适当的检测。一些例子包括循环肿瘤标志物，细胞因子，阿尔茨海默病标志物，心脏标志物，传染病标志物。Psyros是一家新成立的分拆自一家全球制药公司，该公司在精准医疗领域拥有大量业务。该团队在开发护理点体外诊断方面有着非常强大的记录，并认识到精密医学对超灵敏检测的需求尚未得到满足。在这个项目中，我们打算证明在诊断中使用超灵敏检测的突破性新概念的可行性。一旦得到充分发展，这将为目前无法实现的疾病提供精准医疗的机会，从而改善患者的治疗效果，并最终提高他们的生活质量。”

"We now live in an age where personalised precision medicine is a reality for many patients, enabling better health outcomes. This personalisation requires access to appropriate diagnostic tools to select the right patients for the right treatment at the right time. Whilst a large number of disease markers are detectable using existing diagnostic tools for patient selection, there are still a significant number of disease areas which have eluded suitable testing in the clinical setting due to limited sensitivity of the tests. A few examples include circulating tumour markers, Cytokines, Alzheimer's disease markers, cardiac markers , infectious disease markers.Psyros are a newly formed spin-out from a Global Pharmaceutical company who had a large presence in precision medicine. The team have a very strong track record developing point of care _in-vitro_ diagnostics and recognise this unmet need of ultra-sensitive testing for precision medicine.In this project, we intend to prove the feasibility of a ground-breaking new concept for ultra-sensitive detection for use in diagnostics. When fully developed, this will open up opportunities for precision medicine for diseases where this is not currently possible, thereby improving the outcomes for patients and ultimately improving the quality of their lives."